PDB57 LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY  by Wiesner, T et al.
A294 13th Euro Abstracts
PDB55
COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES 
PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A 
BASAL-BOLUS REGIMEN IN GERMANY
Bierwirth RA1, Kostev K2, Dippel FW3, Fuchs S4, Kotowa W4
1Ambulantes Diabteszentrum am Elisabeth-Krankenhaus, Essen, Germany; 2IMS Health 
GmbH & Co. OHG, Frankfurt am Main, Germany; 3Sanoﬁ -Aventis Deutschland GmbH, 
Berlin, Germany; 4IMS Health GmbH & Co. OHG, Nürnberg, Germany
OBJECTIVES: Compare resource utilization and treatment costs with three different 
basal insulins in type-1-diabetics (T1D). METHODS: A cohort study based on a repre-
sentative database (IMS® Disease Analyzer) included T1D who had started an intensi-
ﬁ ed conventional therapy (ICT) with NPH-insulin (NPH), insulin glargine (GLA) or 
insulin detemir (DET) between July 2000 and February 2008 and whose data were 
continuously documented at least 12 months before and 18 months after ICT initiation. 
The variables age, gender, diabetes duration, HbA1c, Body Mass Index (BMI), insurance 
status, geographical region and speciﬁ cation of the practice were collected. Diabetes-
related resource utilization (insulin, test strips, lancets, pens, needles, glucose i.v., glu-
cagon, physician visits and hospitalization) and associated direct treatment costs 
(excluding physicians visits and hospitalization) were determined for a time period of 
12 months for patients receiving NPH, GLA and DET, respectively. The results were 
adjusted applying a multivariate regression model. RESULTS: A total of 1218 T1D 
received an ICT with NPH, 1079 with GLA and 443 with DET, respectively. The 
unadjusted annual direct treatment costs were c1308 for NPH, c1512 for GLA and 
c1729 for DET. After adjusting ICT with GLA showed economic advantages compared 
to NPH (−c234/year; P < 0.0001) or DET (−c425/year; P = 0.2800). The consumption 
of basal insulin and test strips was lower in patients treated with GLA compared to 
NPH (−6.00 U/day; P = 0.3514 and −0.31 strips/day; P = 0.8291) or DET (−3.23 U/
day; P < 0.0001 and −0.59 strips/day; P = 0.0235). CONCLUSIONS: After adjustment 
this analysis of German real-life data showed that ICT with GLA is related to lower 
annual treatment costs than ICT with NPH or DET. In view of the equal clinical efﬁ cacy 
as reported in several randomized clinical trials [1, 2] and the economic advantages, 
GLA should be regarded as the favored therapeutic option in ICT for T1D in Germany.
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OBJECTIVES: Diabetic nephropathy is the most frequent cause of End Stage Renal 
Disease (ESRD). As ESRD incidence continuously increases, more resources are needed 
for treatment. The objective was to evaluate the economic impact of losartan added to 
the standard care administered to diabetic subjects with ESRD. The analysis has involved 
more than 500 million inhabitants. METHODS: We used standard methods to conduct 
an economic evaluation comparing the economic outcomes deriving from the adminis-
tration of losartan added to standard care versus standard care alone in patients with 
type 2 diabetes mellitus (DM) and nephropathy over 3.4 years. The study was conducted 
from the perspective of the third-party payer hence. The clinical outcome data were 
based on the results from the RENAAL trial. Direct medical costs are referred to the 
purchase costs of losartan and the cost of hospitalizations. The costs were discounted 
back at an annual rate of 3%. Also sensitivity analysis was performed. RESULTS: 
RENAAL study established that losartan confers strong renal protection in patients with 
DM and nephropathy. Losartan results into a cost saving in all countries considered: 3 
c602.98/Italy, c4531.35/France, c3019.66/Germany, c3949.50/Switzerland and 
c3855.50/USA per patient. Results are not sensitive to both clinical and economic 
variables. CONCLUSIONS: In addition to the medical beneﬁ t, this analysis demon-
strates the economic relevance of treatment with losartan in DM patients with 
nephropathy.
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OBJECTIVES: To compare, from the perspective of Statutory Health Insurance (SHI) 
in Germany, direct diabetes-related treatment costs in patients with type 1 diabetes 
mellitus (T1DM) during the ﬁ rst year after the switch from Neutral Protamin Hage-
dorn insulin (NPH) to the respective long acting insulin in the course of a basal-bolus 
insulin regimen (ICT) with insulin glargine or insulin detemir as the basal insulin 
component. METHODS: Natural units of resource consumption incurred by basal 
and bolus insulin, needles, lancets, and test strips were modelled over a period of 1 
year in each of the two cost-minimization analyses, based on the results of two con-
trolled clinical trials [1, 2]. Resources were valued in prices of 15 January 2010 rel-
evant to SHI in the outpatient sector. In the base-case analyses, average values of all 
the model parameters were applied. In comprehensive sensitivity analyses (impact 
analysis, analysis of extremes, Monte Carlo simulation), the robustness of the base-
case results was tested. RESULTS: In the base-case analyses, there were savings of 
c378 or 15% and c311 or 14%, respectively, per patient and year obtained by insulin 
glargine compared to insulin detemir. Savings in favour of GLA turned out to be 
robust in the sensitivity analyses. Even in the analyses of extremes, there were always 
savings obtained by insulin glargine, irrespective of insulin detemir being given once, 
once to twice, or twice daily. When simulating real-life conditions the savings obtained 
by insulin glargine instead of insulin detemir were maintained. CONCLUSIONS: 
Treatment of T1DM patients with insulin glargine as the basal insulin component of 
an ICT may lead to substantial savings from the German SHI perspective as compared 
to insulin detemir. [1] Pieber et al. Diabet Med 2007;24:635–42; [2] Heller et al. Clin 
Ther 2009;31:2086–97.
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OBJECTIVES: To conduct pharmacoepidemiological research and cost-minimization 
analysis of oral antidiabetic medications and insulins in Lithuania. METHODS: Medi-
cations were grouped according to the ATC classiﬁ cation system. Our research results 
were reported in DDDs per 1000 inhabitants per day (DDD/TID). Calculations of 
drug prices and total expenditures on antidiabetic medications were made by using 
data from National Patient Funds Price List in 2006–2009 years. Reference pricing 
methodology was used to accomplish our cost-minimization analysis. RESULTS: 
Total consumption of hypoglycaemic agents increased by 33% from 21.54 DDD/TID 
in 2006 to 28.72 DDD/TID in 2009. Utilization of insulin increased by 30% reaching 
the value 9.43 DDD/TID in 2009 and oral antidiabetic medications increased by 
35%—19.29 DDD/TID in 2009. Total expenditures on hypoglycaemic agents 
increased by 23% from LTL 57.138 mlln in 2006 to LTL 70.531 mlln in 2009 (1EUR 
= 3.4528LTL). Single DDD prices ranged from 0.70 LTL/DDD to 5.01 LTL/DDD of 
oral antidiabetics, and from 5.67 LTL/DDD to 2.97 LTL/DDD for insulins. With refer-
ence to meta-analysis and NICE recommendations, considering the similar efﬁ cacy 
and safety within drug classes, cost-minimization analysis using the reference-based 
pricing could be implemented and total expenditures could be decreased by 27% 
(saving LTL 19 mlln. yearly). CONCLUSIONS: Our ﬁ ndings suggest that implementa-
tion of reference-based pricing could be a strong ﬁ scal measure helping to rationalize 
increasing direct health care expenditures by 27%.
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OBJECTIVES: To perform a systematic literature review of health economic evalua-
tions comparing GLA with NPH as the basal component of an ICT in patients with 
type 1 diabetes. METHODS: The search was performed between January 1, 2000 and 
December 1, 2009 via Embase, Medline, the Cochrane Library, the databases of 
German Medical Science and of DAHTA (Deutsche Agentur für Health Technology 
Assessment), and abstract books of relevant scientiﬁ c congresses. The inclusion of 
retrieved studies was based on predeﬁ ned criteria. The included studies were assessed 
according to established methodological and quality aspects. RESULTS: A total of 
seven health-economic evaluations from four different countries were included: six 
modeling studies, all of them cost-utility analyses (CUA), and one cost-minimization 
analysis (CMA) based on a claims data analysis. One CUA showed dominance of GLA 
because of higher utilities and lower costs. The other ﬁ ve CUAs varied in their addi-
tional costs per quality adjusted life-year (QALY) gained for treatment with GLA 
between c3.859 and c57.002 (incremental cost-effectiveness ratio, ICER). The CMA 
revealed about c160 higher diabetes-speciﬁ c costs per year for GLA in the German 
Statutory Health Insurance (SHI) setting. All the included studies showed good quality 
despite a few constraints. Nevertheless, they all contained enough explanatory power 
to evaluate the effectiveness of GLA in comparison to NPH. CONCLUSIONS: Despite 
some differences concerning evaluation methods (CUA or CMA), data sources (ran-
domized controlled trial, claims data) and country speciﬁ c conditions (pricing and 
reimbursement situation) the identiﬁ ed health economic analyses showed high confor-
mity concerning the main target parameter. Most of the studies (5 of 7) showed a 
good to very good cost-effectiveness in favour of GLA compared to NPH depending 
on the respective design of the health economic analysis chosen. ACKNOWLEDG-
MENT: This study was supported by Sanoﬁ -Aventis Deutschland GmbH, Berlin, 
Germany.
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OBJECTIVES: Due to limited health care resources economic evaluations of alterna-
tive drug treatment methods become more important, especially in chronic diseases 
like diabetes mellitus. Therefore, a systematic literature review of health economic 
evaluations comparing GLA with DET as the basal component of an ICT in patients 
